PRINSTON PHARMACEUTICAL ANNOUNCES THE APPROVAL OF GENERIC LEXAPRO® TABLETS IN THE UNITED STATES
CRANBURY, NJ – February 08, 2016 – Prinston Pharmaceutical, Inc. is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its generic equivalent of Lexapro® (Escitalopram Tablets USP), 5 mg, 10 mg and 20 mg. The Company is preparing for commercialization of this product by the end of the first quarter 2016 through Prinston's generic division, Solco Healthcare, LLC.
"We are pleased to receive FDA approval of generic escitalopram tablets, our first ANDA approval for 2016. We are excited about this approval and look forward to continuing to bring valued added generic products to the market”, said Jun Du, President and Chief Executive Officer of Prinston.
According to IMS Health (NSP), U.S. brand and generic sales of escitalopram tablets products were approximately $204.4 million for the 12 months ending in September 2015.
About Prinston Pharmaceutical, Inc. Prinston Pharmaceutical, Inc. is a fast growing, emerging global pharmaceutical company, located in Cranbury, New Jersey, USA. We are a fully integrated pharmaceutical company engaged in product development, product registration, manufacturing, marketing and sales of high quality affordable generic prescription products to our customers. Our highly experienced R&D team meets market needs through innovation, rapidly bringing high quality products to the US market, to help patients get the best pharmaceutical products at an affordable cost. We deliver and maintain the highest quality standard and integrity in all of our products, which are manufactured by the company or its partners around the world in world-class cGMP (current Good Manufacturing Practices) manufacturing facilities.Tweet